medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2021, Number 3

<< Back Next >>

Acta Med 2021; 19 (3)

Pharmacological treatments for COVID-19

Morales FJA, Cruz SAX, Chávez AJE, Mosqueda MEE, Gutiérrez BD, Joaquín VH, Ramírez VIO, Perón MLÁ, García OZR, Vásquez MLM, Valadez GY, Cortázar MLA, Vite VX, Ángel AAH, García LML, Bautista CP, Díaz RJB, Wong CRM

Language: Spanish
References: 79
Page: 408-420
PDF size: 368.42 Kb.


ABSTRACT

SARS-CoV-2 is the coronavirus that causes coronavirus disease 2019 (COVID-19), which is a disease of global concern and declared as a pandemic in 2020. For adequate control, personal protection measures have been taken and a great variety of drugs have been investigated to act in the pathogenic process to prevent the adhesion, replication and progression of the virus in the different stages of the disease, as well as the generation of effective neutralizing antibodies against it. The emergence of genetic variants has generated the need for advances in technologies for the development and research of new therapeutic targets. Currently, there is no specific drug for the pharmacological treatment of COVID-19, however, different drugs are used that have prevented the progression of the disease, recovery of illness, decreased mortality and increased survival.


REFERENCES

  1. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021; 19 (3): 155-170. doi: 10.1038/s41579-020-00468-6.

  2. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203 (2): 631-637. doi: 10.1002/path.1570.

  3. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020; 9 (3): 231. doi: 10.3390/pathogens9030231.

  4. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020; 11: 1648. doi: 10.3389/fimmu.2020.01648.

  5. McIntosh K. Coronavirus disease 2019 (COVID-19): epidemiology, virology, clinical features, diagnosis, and prevention. In: Hirsch MS, ed. UpToDate. Waltham, MA: UpToDate; 2020 [Modificado 23 de abril de 2021; consultado 25 de abril de 2021]. Available in: https://www.uptodate.com

  6. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020; 383 (18): 1757-1766. doi: 10.1056/NEJMcp2009249.

  7. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020; 323 (22): 2329-2330. doi: 10.1001/jama.2020.6825.

  8. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017; 377 (6): 562-572. doi: 10.1056/NEJMra1608077.

  9. Barrot L, Asfar P, Mauny F, Winiszewski H, Montini F, Badie J et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N Engl J Med. 2020; 382 (11): 999-1008. doi: 10.1056/NEJMoa1916431.

  10. Montejo JC, García de Lorenzo A, Marco P, Ortiz C. Manual de medicina intensiva. 5a ed. Barcelona: Elsevier; 2017.

  11. OPS. Algoritmo de manejo de pacientes con sospecha de infección por COVID-19 en el primer nivel de atención y en zonas remotas de la Región de las Américas. Organización Panamericana de la Salud, 2020. [Acceso 28 de abril de 2021] Disponible en: https://iris.paho.org/bitstream/handle/10665.2/52501/OPSIMSEIHCOVID-19200012_spa.pdf?sequence=6&isAllowed=y

  12. Masclans JR, Pérez-Terán P, Roca O. The role of high flow oxygen therapy in acute respiratory failure. Med Intensiva. 2015; 39 (8): 505-515. doi: 10.1016/j.medin.2015.05.009.

  13. Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med. 2018; 36 (2): 226-233. doi: 10.1016/j.ajem.2017.07.083.

  14. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015; 372 (23): 2185-2196. doi: 10.1056/NEJMoa1503326.

  15. Kapil S, Wilson JG. Mechanical ventilation in hypoxemic respiratory failure. Emerg Med Clin North Am. 2019; 37 (3): 431-444. doi: 10.1016/j.emc.2019.04.005.

  16. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017; 195 (9): 1253-1263. doi: 10.1164/rccm.201703-0548ST.

  17. Sartini C, Tresoldi M, Scarpellini P, Tettamanti A, Carco F, Landoni G et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the Intensive Care Unit. JAMA. 2020; 323 (22): 2338-2340. doi: 10.1001/jama.2020.7861.

  18. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013; 368 (23): 2159-2168. doi: 10.1056/NEJMoa1214103.

  19. World Health Organization. Clinical management clinical management: living guidance COVID-19. World Health Organization; 2021.

  20. Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bell D et al. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: a systematic review and meta-analysis. Crit Care Med. 2017; 45 (9): 1538-1545. doi: 10.1097/CCM.0000000000002554.

  21. Brown RM, Wang L, Coston TD, Krishnan NI, Casey JD, Wanderer JP et al. Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial. Am J Respir Crit Care Med. 2019; 200 (12): 1487-1495. doi: 10.1164/rccm.201903-0557OC.

  22. Han H, Yang L, Liu R, Liu F, Wu KL, Li J et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020; 58 (7): 1116-1120. doi: 10.1515/cclm-2020-0188.

  23. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18 (5): 1094-1099. doi: 10.1111/jth.14817.

  24. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383 (19): 1813-1826. doi: 10.1056/NEJMoa2007764.

  25. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020; 383 (19): 1827-1837. doi: 10.1056/NEJMoa201530

  26. Interleukin-6 Inhibitors. COVID-19 treatment guidelines. 2021. Available in: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/interleukin-6-inhibitors/

  27. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020; 383 (24): 2333-2344. doi: 10.1056/NEJMoa2028836.

  28. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324 (13): 1330-1341. doi: 10.1001/jama.2020.17023.

  29. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020; 324 (13): 1307-1316. doi: 10.1001/jama.2020.17021.

  30. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382 (24): 2327-2336. doi: 10.1056/NEJMoa2007016.

  31. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383 (19): 1813-1826. doi: 10.1056/NEJMoa2007764.

  32. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020; 383 (19): 1827-1837. doi: 10.1056/NEJMoa2015301.

  33. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384 (9): 795-807. doi: 10.1056/NEJMoa2031994.

  34. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) treatment guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021. [Consult Apr 27 2021] Available in: www.covid19treatmentguidelines.nih.gov

  35. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020; 396 (10259): 1345-1352. doi: 10.1016/S0140-6736(20)32013-4.

  36. Mitja O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. 2021; 384 (5): 417-427. doi: 10.1056/NEJMoa2021801.

  37. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020; 383 (21): 2041-2052. doi: 10.1056/NEJMoa2019014.

  38. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397 (10274): 605-612. doi: 10.1016/S0140-6736(21)00149-5.

  39. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 397 (10279): 1063-1074. doi: 10.1016/S0140-6736(21)00461-X.

  40. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017; 377 (6): 562-572. doi: 10.1056/NEJMra1608077.

  41. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384 (8): 693-704. doi: 10.1056/NEJMoa2021436.

  42. Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021; 384 (16): 1503-1516. doi: 10.1056/NEJMoa2028700.

  43. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021; 384 (16): 1491-1502. doi: 10.1056/NEJMoa2100433.

  44. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 384 (1): 20-30. doi: 10.1056/NEJMoa2030340.

  45. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev. 2014; (8): CD006190. doi: 10.1002/14651858.CD006190.pub2.

  46. Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. The preprint server for health service. medRxiv. 2021. Available in: https://doi.org/10.1101/2021.01.26.21250494

  47. Colchicina (Colcrys) [prospecto]. Administración de Alimentos y Medicamentos. 2012. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf

  48. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019; 11 (478): eaau5266. doi: 10.1126/scitranslmed.aau5266.

  49. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021; 8 (2): ofab050. doi: 10.1093/ofid/ofab050.

  50. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020; 324 (22): 2292-2300. doi: 10.1001/jama.2020.22760.

  51. Zhou Q, MacArthur MR, He X, Wei X, Zarin P, Hanna BS et al. Interferon-α2b Treatment for COVID-19 is associated with improvements in lung abnormalities. Viruses. 2020; 13 (1): 44. doi: 10.3390/v13010044.

  52. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020; 64 (9): e01061-20. doi: 10.1128/AAC.01061-20.

  53. COVID-19 Treatment Guidelines. Interferons. 2020. Available in: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/interferons/

  54. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020; 2 (7): e393-e400. doi: 10.1016/S2665-9913(20)30164-8.

  55. Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021: keab447. doi: 10.1093/rheumatology/keab447.

  56. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020; 214: 108393. doi: 10.1016/j.clim.2020.108393.

  57. Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014; 462 (1): 1-13. doi: 10.1042/BJ20140712.

  58. Bousoik E, Montazeri Aliabadi H. "Do we know jack" about Jak? A closer look at JAK/STAT signaling pathway. Front Oncol. 2018; 8: 287. doi: 10.3389/fonc.2018.00287.

  59. Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr. 2008; 87 (3): 517-533. doi: 10.1093/ajcn/87.3.517.

  60. COVID-19 Treatment Guidelines. Kinase inhibitors. 2021. Available in: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/kinase-inhibitors/

  61. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020; 158 (3): 1143-1163. doi: 10.1016/j.chest.2020.05.559.

  62. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020; 18 (7): 1743-1746. doi: 10.1111/jth.14869.

  63. Mammen, EF. Current development in antithrombotic therapy. Semin Thromb Hemost. 2004; 30 (6): 605-607. Available in: https://doi.org/10.1055/s-2004-861501

  64. SETH. Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19. Sociedad Española de Trombosis y Hemostasia. 2020. Disponible en: https://www.covid-19.seth.es/recomendaciones-de-tromboprofilaxis-y-tratamiento-antitrombotico-en-pacientes-con-covid-19/

  65. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021; 384 (7): 610-618. doi: 10.1056/NEJMoa2033700.

  66. Lilly Investors. Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in phase 3 trial for early COVID-19. 2021. Available in: https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced

  67. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G et al. S102 Vitamin d supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data. Thorax. 2016; 71 (Suppl 3): A60.2-A61. Available in: doi.org/10.1136/thoraxjnl-2016-209333.108

  68. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. J Pharmacol Pharmacother. 2012; 3 (4): 300-303. doi: 10.4103/0976-500X.103685.

  69. Xiao L, Xing C, Yang Z, Xu S, Wang M, Du H et al. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. Br J Nutr. 2015; 114 (7): 1026-1034. doi: 10.1017/S000711451500207X.

  70. Bonvecchio A, Pacheco S, Irizarry L, Herrera M, Tijerina M, Bernal J et al. Recomendaciones de micronutrientes para grupos vulnerables en contexto de desnutrición, durante la pandemia de COVID-19 en Latinoamérica. Arch Latinoam Nutr. 2019; 69: 259-273.

  71. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021; 325 (11): 1053-1060. doi: 10.1001/jama.2020.26848.

  72. Ran L, Zhao W, Wang H, Zhao Y, Bu H. Vitamin C as a supplementary therapy in relieving symptoms of the common cold: a meta-analysis of 10 randomized controlled trials. Biomed Res Int. 2020; 2020: 8573742. doi: 10.1155/2020/8573742.

  73. Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013; 2013 (1): CD000980. doi: 10.1002/14651858.CD000980.pub4.

  74. Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017; 9 (11): 1211. doi: 10.3390/nu9111211.

  75. Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID a to Z randomized clinical trial. JAMA Netw Open. 2021; 4 (2): e210369. doi: 10.1001/jamanetworkopen.2021.0369.

  76. Comité Internacional para la Elaboración de Consensos y Estandarización en Nutriología (CIENUT). Posición de expertos sobre el manejo nutricional del coronavirus COVID-19. Lima: Fondo editorial IIDENUT. 2020. Disponible en: https://cienut.org/comite_internacional/declaraciones/pdf/declaracion2.pdf

  77. Fowler AA, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A et al. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019; 322 (13): 1261-1270. doi: 10.1001/jama.2019.11825.

  78. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010; 6 (11): e1001176. doi: 10.1371/journal.ppat.1001176.

  79. Frontera JA, Rahimian JO, Yaghi S, Liu M, Lewis A, de Havenon A et al. Treatment with zinc is associated with reduced in-hospital mortality among COVID-19 patients: a multi-center cohort study. Res Sq. 2020: rs.3.rs-94509. doi: 10.21203/rs.3.rs-94509/v1.




2020     |     www.medigraphic.com